Posted by Michael Wonder on 26 Sep 2016
US FDA approves labeling update of Rexulti (brexpiprazole) for maintenance treatment of schizophrenia
24 September 2016 - Labeling update includes clinical data on use of Rexulti in adult patients with schizophrenia in the maintenance phase of treatment.
Lundbeck & Otsuka announced today that the US FDA approved the labeling update of Rexulti (brexpiprazole) to reflect clinical data for maintenance treatment of schizophrenia.
The approval was based on results from a long-term randomized withdrawal trial in adults with schizophrenia aged 18 to 65 years.
